NYSE · PEN
Healthcare · Medical - Devices
$322.58
Up+$0.22 (+0.07%)
Updated Sep 2, 2026, 9:01 PM
SID Score
5.2/10
Composite research score
Smart Money
55/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
PEN closed at $322.58 after 21 trading sessions, down 0.51% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 1, 2026 | $325.00 | $325.00 | $322.19 | $322.58 | 150.76K |
| Aug 31, 2026 | $320.99 | $323.84 | $320.97 | $323.10 | 477.15K |
| Aug 28, 2026 | $320.83 | $322.25 | $320.83 | $321.68 | 234.13K |
| Aug 27, 2026 | $323.00 | $323.13 | $321.00 | $321.00 | 476.7K |
| Aug 26, 2026 | $322.00 | $323.59 | $321.89 | $323.05 | 513.09K |
| Aug 25, 2026 | $323.70 | $324.86 | $323.32 | $324.37 | 271.58K |
| Aug 24, 2026 | $324.91 | $324.91 | $323.42 | $323.75 | 144.27K |
| Aug 21, 2026 | $323.87 | $325.66 | $323.87 | $325.18 | 167.12K |
| Aug 20, 2026 | $327.12 | $327.12 | $323.76 | $323.76 | 210.04K |
| Aug 19, 2026 | $325.54 | $327.77 | $325.54 | $326.84 | 305.26K |
| Aug 18, 2026 | $328.60 | $328.60 | $324.75 | $324.75 | 176.79K |
| Aug 17, 2026 | $326.36 | $327.61 | $326.36 | $327.17 | 187.63K |
| Aug 14, 2026 | $327.28 | $328.11 | $326.72 | $327.02 | 251.61K |
| Aug 13, 2026 | $327.25 | $327.575 | $325.95 | $326.75 | 209.55K |
| Aug 12, 2026 | $325.60 | $327.5475 | $325.25 | $326.58 | 230.04K |
| Aug 11, 2026 | $325.79 | $326.84 | $325.39 | $326.28 | 240.4K |
| Aug 10, 2026 | $324.90 | $326.495 | $324.90 | $325.98 | 194.7K |
| Aug 7, 2026 | $324.93 | $325.74 | $324.465 | $324.66 | 239.51K |
| Aug 6, 2026 | $324.44 | $325.5725 | $323.855 | $324.86 | 262.16K |
| Aug 5, 2026 | $323.36 | $323.8325 | $322.23 | $323.21 | 282.96K |
| Aug 4, 2026 | $321.57 | $324.35 | $321.35 | $324.22 | 363.25K |
The latest Smart Investors Daily articles mentioning PEN.
PEN research
Company profile and research snapshot.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
| Jun 11, 2026 | RBC Capital | Sector Perform | — |
| May 7, 2026 | Citigroup | Neutral | — |
| May 7, 2026 | Evercore ISI Group | Outperform | — |
| Feb 26, 2026 | Evercore ISI Group | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 25, 2026
Incuvate, LLC today announced that it has filed a patent-infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California.The lawsuit, filed August 19, 2026, alleges that
Yahoo · Aug 14, 2026
The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.
Yahoo · Aug 10, 2026
TFX vs. PEN: Which Stock Is the Better Value Option?
Yahoo · Jul 30, 2026
Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PEN.
